Author:
Corrêa-Castro Gabriela,Silva-Freitas Maria Luciana,de Paula Ludmila,Soares Pereira Leonardo,Dutra Maria Rita Teixeira,Albuquerque Hermano Gomes,Cota Glaucia,de Azevedo Martins Caroline,Da-Cruz Alda Maria,Gomes-Silva Adriano,Santos-Oliveira Joanna Reis
Abstract
AbstractVisceral leishmaniasis (VL) is an infectious disease caused by Leishmania infantum. Clinically, VL evolves with systemic impairment, immunosuppression and hyperactivation with hypergammaglobulinemia. Although renal involvement has been recognized, a dearth of understanding about the underlying mechanisms driving acute kidney injury (AKI) in VL remains. We aimed to evaluate the involvement of immunoglobulins (Igs) and immune complexes (CIC) in the occurrence of AKI in VL patients. Fourteen VL patients were evaluated between early treatment and 12 months post-treatment (mpt). Anti-Leishmania Igs, CIC, cystatin C, C3a and C5a were assessed and correlated with AKI markers. Interestingly, high levels of CIC were observed in VL patients up to 6 mpt. Concomitantly, twelve patients met the criteria for AKI, while high levels of cystatin C were observed up to 6 mpt. Plasmatic cystatin C was positively correlated with CIC and Igs. Moreover, C5a was correlated with cystatin C, CIC and Igs. We did not identify any correlation between amphotericin B use and kidney function markers in VL patients, although this association needs to be further explored in subsequent studies. Our data reinforce the presence of an important renal function impairment during VL, suggesting the involvement of Igs, CIC, and C5a in this clinical condition.
Funder
Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Instituto Federal de Educação, Ciência e Tecnologia do Rio de Janeiro
Publisher
Springer Science and Business Media LLC
Reference103 articles.
1. World Health Organization. Leishmaniasis. https://www.who.int/health-topics/leishmaniasis#tab=tab_1 (2023).
2. Pan American Health Organization. In Leishmaniases Epidemiological Report on the Region of the Americas. https://iris.paho.org/bitstream/handle/10665.2/56831/PAHOCDEVT220021_eng.pdf?sequence=1&isAllowed=y (2022).
3. Cota, G., Erber, A. C., Schernhammer, E. & Simões, T. C. Inequalities of visceral leishmaniasis case-fatality in Brazil: A multilevel modeling considering space, time, individual and contextual factors. PLoS Negl. Trop. Dis. 15, e0009567 (2021).
4. Ministério da Saúde (BR). Leishmaniose visceral—casos confirmados notificados no sistema de informação de agravos de notificação—Minas Gerais. http://tabnet.datasus.gov.br/cgi/tabcgi.exe?sinannet/cnv/leishvmg.def (2023).
5. Costa, D. L. et al. Predicting death from kala-azar: Construction, development, and validation of a score set and accompanying software. Rev. Soc. Bras. Med. Trop. 49, 728–740 (2016).